INmune Bio | The TYP

Blog Posts

Mar 8, 20226 min read

NFL AS A HIGHLY RELEVANT BIOMARKER IN AD AND OTHER NEUROLOGICAL DISEASES

What is neurofilament-light chain (NfL)? Neurofilaments, the larger group to which NfL belongs, are structural components of neuronal...

Feb 26, 20228 min read

TIML/INKMUNE MAY DRASTICALLY OUTPERFORM CIML – A COMPARISON

Reminder of the NK cell activation threshold as a predictor of survival This, we know. · INKmune generates memory-like NK cells in...

Feb 20, 202216 min read

INKMUNE AS A NEW APPROACH IN NK-TARGETING IMMUNO-ONCOLOGY

Summary: INKmune is an NK-targeting immuno-oncology drug allowing treatment in a wide range of NK-related cancers; INKmune’s production...

Jan 23, 202213 min read

THE TEN BILLION UNICORN IN INMB: ON MY INVESTMENT THESIS AND INMB’s PRICE MOVEMENTS

In my mind's eye, these stairs keep on going into 2023 and the years after. INTRODUCTION The previous five blogs have laid out the...

Dec 29, 202110 min read

THE TEN BILLION DOLLAR UNICORN IN INMUNE BIO, PART IV: A DEEPER DIVE INTO INKMUNE

The immuno-oncology platform INKmune of INmune Bio may be a better, easier to produce and cheaper product candidate than others.

Dec 21, 202114 min read

THE TEN BILLION DOLLAR UNICORN IN INMUNE BIO, PART III: AN INTRODUCTION TO INKMUNE

INTRODUCTION As an immunotherapy drug candidate, INKmune seems by far the most commercially sustainable, undervalued that I am aware of....

Dec 17, 202111 min read

THE TEN BILLION DOLLAR UNICORN IN INMUNE BIO, PART II

Drug XPro of INmune Bio has limitless potential in neurodegenerative diseases such as Alzheimers, ALS, MS, Huntington's, Parkinson's, ...